SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at three events in November. The Company’s agenda is as follows:
BIO-Europe International Partnering Conference
Dr. Robert H. Pierce, Chief Scientific Officer, will present a corporate overview of the Company at the 20th Annual BIO Europe International Partnering Conference, taking place November 3-5, 2014 in Frankfurt, Germany. The presentation is part of the Immunotherapy track and is scheduled to begin at 11:30 AM CET on Tuesday, November 4th.
BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry. For more information, please visit http://www.ebdgroup.com/bioeurope/index.php
Drexel Hamilton Micro-Cap Investor Forum
Jordyn Kopin, Associate Director of Corporate Communications, will present a corporate overview of the Company at the Drexel Hamilton Micro-Cap Investor Forum, taking place November 13th, 2014 in New York City, New York. The presentation is scheduled to begin at 10 AM EST.
The Drexel Hamilton Micro-Cap Investor Forum is an interactive industry conference for institutional investors. The conference will feature one-on-one meeting opportunities with presenting companies and provide an interactive environment meant to facilitate networking and discussion. For more information, please visit http://drexelhamilton.com/research/conferences/
Brean Capital Life Sciences Summit Conference
Punit Dhillon, President and CEO, will present a corporate overview of the company at the Brean Capital Life Sciences Summit. The event will take place November 24th, 2014 in New York City, New York.
The Brean Capital Life Sciences Summit is an industry-specific investment conference designed to facilitate the interaction of company management and institutional investors. The goal of each Brean Capital conference is to provide institutional investors with high-level access to senior management and industry experts and designed to connect the dots and provide original outlook and depth. For more information please visit: http://www.breancapital.com/profile/conferences/
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.